Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.629,21
    -107,19 (-0,32%)
     

  • Dow Jones

    38.675,68
    +450,02 (+1,18%)
     

  • Nasdaq

    16.156,33
    +315,37 (+1,99%)
     

  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     

  • Petrolio

    77,99
    -0,96 (-1,22%)
     

  • Bitcoin EUR

    59.264,75
    +2.635,50 (+4,65%)
     

  • CMC Crypto 200

    1.359,39
    +82,41 (+6,45%)
     

  • Oro

    2.310,10
    +0,50 (+0,02%)
     

  • EUR/USD

    1,0765
    +0,0038 (+0,36%)
     

  • S&P 500

    5.127,79
    +63,59 (+1,26%)
     

  • HANG SENG

    18.475,92
    +268,79 (+1,48%)
     

  • Euro Stoxx 50

    4.921,48
    +30,87 (+0,63%)
     

  • EUR/GBP

    0,8577
    +0,0023 (+0,27%)
     

  • EUR/CHF

    0,9735
    -0,0024 (-0,25%)
     

  • EUR/CAD

    1,4726
    +0,0064 (+0,44%)
     

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc.
·1 minuto per la lettura
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.

RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6th in Boston at 3:00 p.m. ET and the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13th in New York at 12:30 p.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com